300142 沃森生物
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,433,349-33.88%4,113,7725,086,4453,462,8312,939,021
减:营业总成本1,178,656-22.77%3,152,2133,806,2232,627,6381,912,676
    其中:营业成本286,7285.20%597,556609,469394,339399,810
               财务费用(27,765)-21.26%(70,993)(62,981)(38,721)(30,698)
               资产减值损失(67,337)1,774.78%(162,640)(61,466)(11,845)(4,919)
公允价值变动收益(102,010)477.86%(234,750)(199,335)(280,737)279,890
投资收益3,654-42.25%7,11411,79757,8765,400
    其中:对联营企业和合营企业的投资收益1-100.32%382(1,074)(932)181
营业利润188,417-70.19%613,9661,099,440710,2751,376,282
利润总额277,693-55.78%598,9761,070,465708,9451,373,304
减:所得税费用20,177-69.18%87,651132,239107,593162,117
净利润257,516-54.22%511,325938,226601,3521,211,187
减:非控股权益86,956-18.97%91,935209,574173,604208,000
股东净利润170,560-62.53%419,390728,652427,7481,003,187

市场价值指针
每股收益 (元) *0.107-62.52%0.2620.4550.2730.652
每股派息 (元) *----0.0100.0100.0270.070
每股净资产 (元) *5.9200.65%5.8175.6525.2984.233
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容